Jupiter, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to invite investors to a webinar on January 6, 2026, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Jupiter Neuroscience Chairman and CEO Chister Rosén who will provide investors with an overview of Jupiter Neurosciences’ scientific platform, c ...

IPO Edge hosted a fireside chat on Dec. 8 from the Nasdaq Marketsite with Christer Rosen, Chairman and Chief Executive Officer, and Alison Silva, President and Chief Business Officer of Jupiter Neurosciences, Inc. (Nasdaq: JUNS). The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed the company’s treatments for neuroinflammation and rare diseases through JOTROL, its patented resveratrol delivery platform. They also talked about the company’s clinical pipeline with $50B+ com ...

Core Insights - Jupiter Neurosciences is advancing its JOTROL platform into a Phase 2a clinical trial for Parkinson's disease, marking a significant regulatory milestone with FDA clearance [4][5] - The company launched its Nugevia consumer brand, targeting the $8 trillion longevity market, with initial products designed to enhance brand visibility and generate revenue [6][7] - Jupiter has secured strategic financing of up to $20 million to support its clinical and commercial initiatives, providing flexibility and control over capital access [10][11][12] Company Achievements - Jupiter Neurosciences completed its first full year as a public company, establishing a foundation for long-term value creation and executing major initiatives [2][3] - The JOTROL platform has demonstrated a nine-fold improvement in bioavailability and effective blood-brain barrier penetration, supporting its therapeutic potential [5][20] - The Nugevia product line includes three initial offerings—GLO, PWR, and MND—integrating JOTROL with other bioavailable ingredients to support various aspects of health [7][21] Market Positioning - The Nugevia brand is supported by high-profile ambassadors, enhancing its market presence and performance-driven identity [8] - A dedicated website for Nugevia was launched, facilitating pre-orders and establishing a subscription-based model for recurring revenue [9] - Jupiter's dual-path strategy focuses on both therapeutic applications for CNS disorders and consumer longevity products, positioning the company for growth in both sectors [17][22] Financial Strategy - The strategic financing agreement with Yorkville Advisors allows Jupiter to access capital as needed, ensuring stability during its growth phase [10][11] - The financing structure is designed to be non-toxic and fully controlled by the company, allowing for advantageous capital access [11][12] - The company aims to strengthen its financial position while supporting ongoing operations and clinical trials without compromising shareholder interests [12]

Core Insights - Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing JOTROL™, a resveratrol-based therapeutic platform aimed at neuroinflammation and mitochondrial dysfunction [1][4] - The company will present at the Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 2-3, 2025, providing opportunities for one-on-one meetings with investors [1][2] Company Overview - Jupiter Neurosciences is pursuing a dual-path strategy to address neuroinflammation and promote healthy aging, targeting CNS disorders and rare diseases while also entering the consumer longevity market with its Nugevia product line [4] - The therapeutic pipeline includes a Phase IIa trial for Parkinson's disease and indications such as Alzheimer's Disease and Friedreich's Ataxia [4] Product Details - JOTROL™ has demonstrated over nine times higher bioavailability compared to earlier resveratrol products, addressing the issue of poor bioavailability that has hindered regulatory approval for resveratrol [6] - The Nugevia product line leverages the same clinically validated delivery technology as JOTROL™, offering support for cognitive health, skin vitality, and cellular energy [7]

As filed with the Securities and Exchange Commission on November 26, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 47-4828381 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Jupiter Neu ...

Financial Performance - For the three months ended September 30, 2025, research and development expenses increased to $816,697, a rise of 789% compared to $91,911 in the same period of 2024[140] - General and administrative expenses for the same period rose to $1,480,356, reflecting a 269% increase from $401,636 in the prior year[141] - Total operating expenses for the three months ended September 30, 2025, were $2,297,053, up 365% from $493,547 in the same period of 2024[139] - The net loss for the three months ended September 30, 2025, was $2,288,034, compared to a net loss of $591,021 for the same period in 2024, representing an increase of 287%[139] - For the nine months ended September 30, 2025, research and development expenses were $2,042,890, a 600% increase from $291,655 in the same period of 2024[148] - General and administrative expenses for the nine months ended September 30, 2025, totaled $4,057,046, up 202% from $1,341,271 in the prior year[149] - The net loss for the nine months ended September 30, 2025, was $6,069,866, compared to a net loss of $911,998 for the same period in 2024, indicating a 566% increase[147] Cash Flow and Financing - Net cash used in operating activities during the nine months ended September 30, 2025 was $3,045,713, a substantial increase from $215,225 used in the same period in 2024[161] - Net cash provided by financing activities was $0 for the nine months ended September 30, 2025, compared to $187,000 in the same period in 2024[162] - The company has an accumulated deficit of $32,091,995 since inception, raising substantial doubt about its ability to continue as a going concern for at least twelve months[155] - The company generated no revenues from product sales since inception, highlighting its reliance on external financing[155] - The company is dependent on raising additional funds to sustain operations and may need to delay or terminate development programs if unable to secure financing[156] Interest Income and Expenses - Interest income for the three months ended September 30, 2025, was $10,212, a significant increase from $23 in the same period of 2024, reflecting a 44,300% rise[142] - Interest expense for the three months ended September 30, 2025, decreased to $1,193 from $107,382 in the prior year, representing a 99% reduction[143] Business Development and Strategy - The company has initiated business development activities in the Asian region, aiming to accelerate drug development and commercialization efforts[165] - The company has entered into service agreements that include equity investments in exchange for services, which are expected to facilitate potential out-licensing deals[166] - The CEO has loaned the company $146,432 as of September 30, 2025, with an interest rate of 3% per year[167] - The company has no off-balance sheet financing arrangements that could materially affect its financial condition[163] - The Company plans to finance future operations through equity securities, grant awards, and strategic collaborations, although there is no assurance of success in these efforts[133]

Core Insights - Jupiter Neurosciences, Inc. has received FDA clearance for its Investigational New Drug application to initiate a Phase 2a clinical trial of JOTROL for Parkinson's disease [1][2][3] - The Phase 2a trial aims to evaluate the safety and tolerability of JOTROL, with additional endpoints to assess pharmacokinetics and pharmacodynamics [2][3] - JOTROL has shown strong safety and bioavailability in Phase I studies, with preclinical evidence suggesting potential neuroprotective benefits [3][4] Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on neuroinflammation and healthy aging, with a therapeutic pipeline targeting CNS disorders and rare diseases [6] - The company is advancing JOTROL, a proprietary resveratrol formulation, which has demonstrated over nine-fold higher bioavailability compared to traditional resveratrol [4][8] - Jupiter is also expanding into the consumer longevity market with its Nugevia product line, which leverages the same delivery technology as JOTROL [6][9] Market Context - Parkinson's disease affects over 10 million people globally, with no current disease-modifying treatments available, highlighting a significant unmet medical need [5] - The global market for Parkinson's therapeutics is projected to exceed $14 billion by 2030, indicating a strong demand for innovative treatments [5]

Core Insights - Jupiter Neurosciences, Inc. has entered into two strategic financing agreements with Yorkville Advisors Global, LP, allowing access to up to $20 million in capital to support its Phase 2 trial for Parkinson's disease and to accelerate the growth of its Nugevia product line [1][2][6] Financing Details - The financing includes a $4 million pre-paid advance available upon execution of the agreements, with an additional $2 million expected shortly after the effectiveness of a registration statement [3] - The pre-paid advances will be issued at a 7% original issue discount and will bear interest, with a maturity date of 12 months after signing [3] - The company has the option to sell up to $14 million of common stock over a 24-month period under a standby equity purchase agreement (SEPA), with shares issued at a 3.0% discount to market price [4][7] Product and Market Focus - The proceeds from the financing will primarily support the Phase 2 trial of JOTROL, a resveratrol delivery platform for treating Parkinson's disease, and will also be used for marketing and sales growth of the Nugevia nutritional product line [2][6] - Jupiter Neurosciences is advancing a therapeutic pipeline targeting CNS disorders and rare diseases, while also expanding into the consumer longevity market with Nugevia [6][10] JOTROL and Nugevia - JOTROL has demonstrated over nine times higher bioavailability compared to earlier resveratrol products, addressing the issue of poor bioavailability that has hindered regulatory approval [9] - Nugevia leverages the same clinically validated delivery technology as JOTROL, offering targeted support for cognitive health, skin vitality, and cellular energy [10]

Core Insights - Jupiter Neurosciences, Inc. has appointed Jean Fallacara as the brand ambassador for its new consumer longevity supplement line, Nugevia, which aims to enhance clinical and scientific integrity in the longevity market [2][4][5] - Nugevia is built on the JOTROL platform, a patented resveratrol-based micellar delivery system that significantly improves bioavailability, supporting the company's clinical-stage CNS therapies [5][11] - The longevity market is projected to reach $8 trillion by 2030, and Nugevia's consumer-facing strategy is expected to create a revenue stream that supports ongoing clinical development and enhances long-term shareholder value [6][8] Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on addressing neuroinflammation and promoting healthy aging through a dual-path strategy, which includes advancing therapeutics for CNS disorders and expanding into the consumer longevity market with Nugevia [8] - The company’s therapeutic pipeline includes a Phase IIa trial for Parkinson's disease and targets other CNS disorders such as Alzheimer's Disease and Friedreich's Ataxia [8][10] - JOTROL, the foundation for both therapeutic and consumer products, has demonstrated over nine times higher bioavailability compared to earlier resveratrol products, addressing the issue of poor absorption that has historically limited the effectiveness of resveratrol [9][10][11] Product Details - Nugevia's initial formulations—GLO, MND, and PWR—are designed to support cellular resilience through synergistic ingredients optimized for absorption via the JOTROL system [5][11] - The brand emphasizes the importance of real science in wellness innovation, aiming to make human longevity accessible to a broad audience, including athletes and entrepreneurs [5][6]

Core Insights - Jupiter Neurosciences, Inc. is launching its Nugevia e-commerce platform and three nutraceutical supplements, marking a significant expansion into the longevity market valued at $8 trillion [2][3][4] - The Nugevia product line utilizes the patented JOTROL resveratrol delivery platform, which has shown a nine-fold increase in bioavailability, aiming to bring pharmaceutical-grade science to the consumer health sector [3][11] - The launch is seen as a pivotal moment for the company, establishing a new revenue stream that supports ongoing research and development while enhancing financial flexibility [4][5] Company Strategy - Jupiter Neurosciences is executing a dual-path business model that focuses on both CNS therapeutic programs and the consumer longevity market [3][8] - The introduction of Nugevia is intended to create a capital-efficient growth engine, allowing the company to leverage its clinical research for consumer products [4][5] - The company aims to build a diversified and sustainable business that complements its pharmaceutical pipeline [4] Product Details - The Nugevia product line includes Nugevia GLO for skin vitality, Nugevia PWR for mitochondrial health, and Nugevia MND for cognitive support, all utilizing the JOTROL technology [9][12] - Pre-orders for the products are available on the Nugevia website, with shipping expected to start in Fall 2025 [7] Brand Ambassadors - Annika Sörenstam and Chris Webber have been appointed as the first brand ambassadors for Nugevia, enhancing the brand's visibility and credibility [6]